# A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

> **NCT03939871** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 30 (estimated)

## Conditions studied

- Hormone Receptor Positive Advanced Breast Cancer

## Interventions

- **DRUG:** fluvestrant + oral vinorelbine

## Key facts

- **NCT ID:** NCT03939871
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-12
- **Primary completion:** 2020-12-12
- **Final completion:** 2020-12-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03939871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03939871, "A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03939871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*